Skip to main content

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy

Clinical Trial Grant
Duke Scholars

Administered By

Neurology, Epilepsy and Sleep

Awarded By

Biogen, Inc.

Start Date

June 8, 2018

End Date

May 21, 2021
 

Administered By

Neurology, Epilepsy and Sleep

Awarded By

Biogen, Inc.

Start Date

June 8, 2018

End Date

May 21, 2021